Stay updated on Pembrolizumab in MM Residual Disease Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in MM Residual Disease Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in MM Residual Disease Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The NIH banner announcing updates and FAQs about the agency’s terminology transition was removed.
    Difference
    1%
    Check dated 2026-11-07T14:58:07.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-31T15:42:06.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    An NIH-wide notice announces a transition in terminology, saying agencies are using “Super Intelligence” instead of “Artificial Intelligence” and linking to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-24T17:54:07.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov error page’s footer revision identifier changed from v3.7.1 to v3.7.2. The study record still displays a 403 Forbidden message.
    Difference
    0.2%
    Check dated 2026-10-17T17:48:11.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.0 to v3.7.1 while the page continued to show a 403 error.
    Difference
    0.2%
    Check dated 2026-10-10T18:21:16.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error, replacing the expected study record content. This indicates an access issue that prevents viewing the study details.
    Difference
    17%
    Check dated 2026-09-19T22:25:13.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in MM Residual Disease Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in MM Residual Disease Clinical Trial page.